nach oben

Erschienen in:

17.12.2015 | Computed Tomography

Iodine concentration as a perfusion surrogate marker in oncology: Further elucidation of the underlying mechanisms using Volume Perfusion CT with 80 kVp

verfasst von: Wolfgang M. Thaiss, Ulrike Haberland, Sascha Kaufmann, Daniel Spira, Christoph Thomas, Konstantin Nikolaou, Marius Horger, Alexander W. Sauter

Erschienen in: European Radiology | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To assess the value of iodine concentration (IC) in computed tomography data acquired with 80 kVp, as a surrogate for perfusion imaging in hepatocellular carcinoma (HCC) and lymphoma by comparing iodine related attenuation (IRA) with quantitative Volume Perfusion CT (VPCT)-parameters.

Methods

VPCT-parameters were compared with intra-tumoral IC at 5 time points after the aortic peak enhancement (APE) with a temporal resolution of 3.5 sec in untreated 30 HCC and 30 lymphoma patients.

Results

Intra-tumoral perfusion parameters for HCC showed a blood flow (BF) of 52.7 ± 17.0 mL/100 mL/min, blood volume (BV) 12.6 ± 4.3 mL/100 mL, arterial liver perfusion (ALP) 44.4 ± 12.8 mL/100 mL/min. Lesion IC 7 sec after APE was 133.4 ± 57.3 mg/100 mL. Lymphoma showed a BF of 36.8 ± 13.4 mL/100 mL/min, BV of 8.8 ± 2.8 mL/100 mL and IC of 118.2 ± 64.5 mg/100 mL 3.5 sec after APE. Strongest correlations exist for VPCT-derived BF and ALP with IC in HCC 7 sec after APE (r = 0.71 and r = 0.84) and 3.5 sec after APE in lymphoma lesions (r = 0.77). Significant correlations are also present for BV (r = 0.60 and r = 0.65 for HCC and lymphoma, respectively).

Conclusions

We identified a good, time-dependent agreement between VPCT-derived flow values and IC in HCC and lymphoma. Thus, CT-derived ICs 7 sec after APE in HCC and 3.5 sec in lymphoma may be used as surrogate imaging biomarkers for tumor perfusion with 80 kVp.

Key points

• Iodine concentration derived from low kVp CT is regarded as perfusion surrogate

• Correlation with Perfusion CT was performed to elucidate timing and histology dependencies

• Highest correlation was present 7 sec after aortic peak enhancement in hepatocellular carcinoma

• In lymphoma, highest correlation was calculated 3.5 sec after aortic peak enhancement

• With these results, further optimization of Dual energy CT protocols is possible

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64:9–29CrossRefPubMed

Davarpanah AH, Weinreb JC (2013) The role of imaging in hepatocellular carcinoma: the present and future. J Clin Gastroenterol 47:S7–S10CrossRefPubMed

Ippolito D, Sironi S, Pozzi M et al (2008) Hepatocellular carcinoma in cirrhotic liver disease: functional computed tomography with perfusion imaging in the assessment of tumor vascularization. Acad Radiol 15:919–927CrossRefPubMed

Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY (2000) Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7:840–850CrossRefPubMed

Miles KA (2003) Perfusion CT for the assessment of tumour vascularity: which protocol? Br J Radiol 76:S36–S42CrossRefPubMed

Kambadakone AR, Sahani DV (2009) Body perfusion CT: technique, clinical applications, and advances. Radiol Clin N Am 47:161–178CrossRefPubMed

Petralia G, Preda L, D'Andrea G et al (2010) CT perfusion in solid-body tumours. Part I: technical issues. Radiol Med 115:843–857CrossRefPubMed

Ippolito D, Capraro C, Casiraghi A, Cestari C, Sironi S (2012) Quantitative assessment of tumour associated neovascularisation in patients with liver cirrhosis and hepatocellular carcinoma: role of dynamic-CT perfusion imaging. Eur Radiol 22:803–811CrossRefPubMed

Ippolito D, Fior D, Bonaffini PA et al (2014) Quantitative evaluation of CT-perfusion map as indicator of tumor response to transarterial chemoembolization and radiofrequency ablation in HCC patients. Eur J Radiol 83:1665–1671CrossRefPubMed

10.

Syha R, Grunwald L, Horger T et al (2014) Assessment of the nature of residual masses at end of treatment in lymphoma patients using volume perfusion computed tomography. Eur Radiol 24:770–779CrossRefPubMed

11.

Spira D, Adam P, Linder C et al (2012) Perfusion and flow extraction product as potential discriminators in untreated follicular and diffuse large B cell lymphomas using volume perfusion CT with attempt at histopathologic explanation. AJR Am J Roentgenol 198:1239–1246CrossRefPubMed

12.

Mileto A, Mazziotti S, Gaeta M et al (2012) Pancreatic dual-source dual-energy CT: is it time to discard unenhanced imaging? Clin Radiol 67:334–339CrossRefPubMed

13.

Graser A, Becker CR, Staehler M et al (2010) Single-phase dual-energy CT allows for characterization of renal masses as benign or malignant. Investig Radiol 45:399–405

14.

Apfaltrer P, Meyer M, Meier C et al (2012) Contrast-enhanced dual-energy CT of gastrointestinal stromal tumors: is iodine-related attenuation a potential indicator of tumor response? Investig Radiol 47:65–70CrossRef

15.

Lee JA, Jeong WK, Kim Y et al (2013) Dual-energy CT to detect recurrent HCC after TACE: initial experience of color-coded iodine CT imaging. Eur J Radiol 82:569–576CrossRefPubMed

16.

Chandler A, Wei W, Anderson EF, Herron DH, Ye Z, Ng CS (2012) Validation of motion correction techniques for liver CT perfusion studies. Br J Radiol 85:e514–e522CrossRefPubMedPubMedCentral

17.

Kaufmann S, Horger T, Oelker A et al (2015) Characterization of hepatocellular carcinoma (HCC) lesions using a novel CT-based volume perfusion (VPCT) technique. Eur J Radiol 84:1029–1035CrossRefPubMed

18.

Spira D, Grunwald L, Vogel W et al (2014) Midtreatment evaluation of lymphoma response to chemotherapy by volume perfusion computed tomography. J Comput Assist Tomogr 38:123–130CrossRefPubMed

19.

Thomas C, Heuschmid M, Schilling D et al (2010) Urinary calculi composed of uric acid, cystine, and mineral salts: differentiation with dual-energy CT at a radiation dose comparable to that of intravenous pyelography. Radiology 257:402–409CrossRefPubMed

20.

Marin D, Boll DT, Mileto A, Nelson RC (2014) State of the art: dual-energy CT of the abdomen. Radiology 271:327–342CrossRefPubMed

21.

Ippolito D, Sironi S, Pozzi M et al (2008) Perfusion computed tomographic assessment of early hepatocellular carcinoma in cirrhotic liver disease: initial observations. J Comput Assist Tomogr 32:855–858CrossRefPubMed

22.

Spira D, Schulze M, Sauter A et al (2012) Volume perfusion-CT of the liver: insights and applications. Eur J Radiol 81:1471–1478CrossRefPubMed

23.

Ippolito D, Sironi S, Pozzi M et al (2010) Perfusion CT in cirrhotic patients with early stage hepatocellular carcinoma: assessment of tumor-related vascularization. Eur J Radiol 73:148–152CrossRefPubMed

24.

Li Y, Shi G, Wang S, Wang S, Wu R (2013) Iodine quantification with dual-energy CT: phantom study and preliminary experience with VX2 residual tumour in rabbits after radiofrequency ablation. Br J Radiol 86:20130143CrossRefPubMedPubMedCentral

25.

Harders SW, Madsen HH, Nellemann HM et al (2013) Dynamic contrast-enhanced CT in suspected lung cancer: quantitative results. Br J Radiol 86:20130257CrossRefPubMedPubMedCentral

26.

Shi J, Schmid-Bindert G, Fink C et al (2013) Dynamic volume perfusion CT in patients with lung cancer: baseline perfusion characteristics of different histological subtypes. Eur J Radiol 82:e894–e900CrossRefPubMed

27.

Sun X, Liu C, Liang C, Sun C, Liu S, Deng K (2009) Hepatocellular carcinomas: correlation between time to peak hepatocellular carcinomas enhancement and time to peak aortic enhancement. Comput Med Imaging Graph 33:312–316CrossRefPubMed

28.

Knobloch G, Jost G, Huppertz A, Hamm B, Pietsch H (2014) Dual-energy computed tomography for the assessment of early treatment effects of regorafenib in a preclinical tumor model: comparison with dynamic contrast-enhanced CT and conventional contrast-enhanced single-energy CT. Eur Radiol 24:1896–1905CrossRefPubMed

29.

McCollough CH, Leng S, Yu L, Fletcher JG (2015) Dual- and multi-energy CT: principles, technical approaches, and clinical applications. Radiology 276:637–653CrossRefPubMedPubMedCentral

Titel: Iodine concentration as a perfusion surrogate marker in oncology: Further elucidation of the underlying mechanisms using Volume Perfusion CT with 80 kVp
verfasst von: Wolfgang M. Thaiss
Ulrike Haberland
Sascha Kaufmann
Daniel Spira
Christoph Thomas
Konstantin Nikolaou
Marius Horger
Alexander W. Sauter
Publikationsdatum: 17.12.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Radiology / Ausgabe 9/2016
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-015-4154-9

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Iodine concentration as a perfusion surrogate marker in oncology: Further elucidation of the underlying mechanisms using Volume Perfusion CT with 80 kVp